Ik Sup Jin et al., 2020-10-21: Formulation study stating the bioavailability problem directly and testing Soluplus polymeric micelles of fenbendazole for physicochemical properties, pharmacokinetics and toxicity.
Fenbendazole (FEN), a broad-spectrum benzimidazole anthelmintic, suppresses cancer cell growth through various mechanisms but has low solubility and achieves low blood concentrations, which leads to low bioavailability.
Ik Sup Jin et al., 2020-10-21: Formulation study stating the bioavailability problem directly and testing Soluplus polymeric micelles of fenbendazole for physicochemical properties, pharmacokinetics and toxicity. Study type: formulation and pharmacokinetics in vitro plus animal pharmacokinetics. N: not stated in the abstract. Country: Korea (Hanyang University; Seoul National University). Dose: micelles of 68.3 nm with 85.3% encapsulation; dosing details in the full text. Funder: not stated in the record. Declared conflicts: no COI statement in the record. Comparator: free fenbendazole solution. This is the cleanest single statement of the solubility/bioavailability problem the C8 claim names.
